Similar Search Results

Explaining early adoption on new medicines : regulation, innovation and scale

Varol, Nebibe; Costa-Font, Joan; McGuire, Alistair - 2011

. -- pharmaceutical innovation ; regulation ; adoption ; duration analysis …

Persistent link: https://www.econbiz.de/10009127576

The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry

Banerjee, Tannista; Siebert, Ralph - 2014

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

Persistent link: https://www.econbiz.de/10010229875

Is medicines parallel trade "regulatory arbitrage"?

Costa-Font, Joan - 2015

regulation, and not by price differences in line with the hypothesis of "regulatory arbitrage". …

Persistent link: https://www.econbiz.de/10010477153

Private versus social incentives for pharmaceutical innovation

González, Paula; Macho-Stadler, Inés; … - 2015

We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...

Persistent link: https://www.econbiz.de/10011406575

The effect of intellectual property rights on domestic innovation in the pharmaceutical sector

Gamba, Simona - 2016

This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …

Persistent link: https://www.econbiz.de/10011509446

Pharmaceutical innovation, longevity, and medical expenditure in Greece, 1995 - 2010

Lichtenberg, Frank - 2015

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

Persistent link: https://www.econbiz.de/10010473542

Dynamic mergers effects on R&D investments and drug development across research phases in the pharmaceutical industry

Siebert, Ralph; Tian, Zhili - 2020

Pharmaceutical ﬁrms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop ﬁrms' internal drug development capability. We evaluate the effects of M&As on ﬁrms' post-merger R&D...

Persistent link: https://www.econbiz.de/10012219372

Does reference pricing drive out generic competition in pharmaceutical markets? : evidence from a policy reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...

Persistent link: https://www.econbiz.de/10013285854

Regulation and pricing of pharmaceuticals : reference pricing or price cap regulation?

Brekke, Kurt R. (contributor); … - 2007

Persistent link: https://www.econbiz.de/10003499685

Pharmaceutical prices : the impact of the launch strategy - an analysis of German data

Böhler, Yvonne-Beatrice; Lamping, Christian; Wichardt, … - 2019 - This Version: September 24, 2019

pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …

Persistent link: https://www.econbiz.de/10012119750

1
2
3
4
5
6
7
8
9
10
Next
Last